tiprankstipranks
Shanghai Fosun Pharmaceutical Moves Forward with Henlius Merger
Company Announcements

Shanghai Fosun Pharmaceutical Moves Forward with Henlius Merger

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Pick the best stocks and maximize your portfolio:

Shanghai Fosun Pharmaceutical has successfully fulfilled all pre-conditions for the proposed privatisation of Shanghai Henlius Biotech by way of a merger. This significant move, which involves absorbing Henlius and withdrawing its listing, is set to progress with the despatch of relevant documents to shareholders by December 23, 2024. Investors are keenly watching this development as it represents a strategic consolidation in the biotech sector.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskFosun Pharma Boosts Equity in Key Funds
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharma’s New Strategic Agreements with Fosun International
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App